This is a Phase II study of neoadjuvant therapy of AK104 combined with nab-paclitaxel/carboplatin in fertility saving surgery for stage IB2-IB3 cervical cancer (FIGO 2018). The main questions it aims to answer are: * · Evaluate the safety of AK104 combined with nab-paclitaxel/carboplatin in the neoadjuvant treatment of cervical cancer * · Evaluate the tumor regression and Major Pathological Response(MPR) of AK104 combined with nab-paclitaxel/carboplatin as neoadjuvant therapy for cervical cancer.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Adverse Events (AEs)
Timeframe: Up to approximately 6 mouths
Tumor regression rate
Timeframe: within 14 working days after operation
Objective response rate
Timeframe: 4-6 weeks after the second cycle(21 days per cycle) of neoadjuvant treatment
The success rate of fertility sparing surgery
Timeframe: Up to approximately 6 mouths